RhumbLine Advisers’s Harmony Biosciences HRMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.77M | Buy |
119,201
+10,128
| +9% | +$320K | ﹤0.01% | 1563 |
|
|
2025
Q1 | $3.62M | Buy |
109,073
+485
| +0.4% | +$16.1K | ﹤0.01% | 1517 |
|
|
2024
Q4 | $3.74M | Buy |
108,588
+16,537
| +18% | +$569K | ﹤0.01% | 1563 |
|
|
2024
Q3 | $3.68M | Sell |
92,051
-8,643
| -9% | -$346K | ﹤0.01% | 1584 |
|
|
2024
Q2 | $3.04M | Sell |
100,694
-3,421
| -3% | -$103K | ﹤0.01% | 1667 |
|
|
2024
Q1 | $3.5M | Buy |
104,115
+3,570
| +4% | +$120K | ﹤0.01% | 1605 |
|
|
2023
Q4 | $3.25M | Sell |
100,545
-1,836
| -2% | -$59.3K | ﹤0.01% | 1657 |
|
|
2023
Q3 | $3.36M | Buy |
102,381
+7,515
| +8% | +$246K | ﹤0.01% | 1578 |
|
|
2023
Q2 | $3.34M | Buy |
94,866
+10,424
| +12% | +$367K | ﹤0.01% | 1622 |
|
|
2023
Q1 | $2.76M | Buy |
84,442
+4,557
| +6% | +$149K | ﹤0.01% | 1643 |
|
|
2022
Q4 | $4.4M | Buy |
79,885
+413
| +0.5% | +$22.8K | 0.01% | 1353 |
|
|
2022
Q3 | $3.52M | Buy |
79,472
+13,075
| +20% | +$579K | 0.01% | 1437 |
|
|
2022
Q2 | $3.24M | Buy |
66,397
+7,106
| +12% | +$347K | ﹤0.01% | 1495 |
|
|
2022
Q1 | $2.89M | Buy |
59,291
+5,702
| +11% | +$277K | ﹤0.01% | 1620 |
|
|
2021
Q4 | $2.29M | Buy |
53,589
+33,492
| +167% | +$1.43M | ﹤0.01% | 1806 |
|
|
2021
Q3 | $770K | Buy |
20,097
+1,097
| +6% | +$42K | ﹤0.01% | 2347 |
|
|
2021
Q2 | $536K | Buy |
+19,000
| New | +$536K | ﹤0.01% | 2531 |
|